Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524202 | 0.86 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL3525402 | 0.84 | MAPK14 (0.49) | MAPK14PTGER1 | |
| SCHEMBL4374045 | 0.83 | MAPK14 (0.57) | MAPK14PTGER1MRGPRX4 | |
| SCHEMBL3525960 | 0.83 | MAPK14 (0.59) | MAPK14PTGER1 | |
| SCHEMBL3523601 | 0.82 | MAPK14 (0.43) | MAPK14PTGER1 | |
| SCHEMBL3527353 | 0.80 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL5204564 | 0.79 | MAPK14 (0.44) | MAPK14PTGER1MRGPRX4 | |
| SCHEMBL3519136 | 0.79 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL4376962 | 0.78 | MAPK14 (0.67) | MAPK14PTGER1 | |
| SCHEMBL3521725 | 0.77 | MAPK14 (0.57) | MAPK14PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885PTGER1 245/4885MRGPRX4 657/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885PTGER1 215/4885MRGPRX4 711/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885PTGER1 245/4885MRGPRX4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.